2nd Annual Targeted Radiopharmaceuticals Summit US

Memo

With the space continuing its upward trajectory with more compounds moving through the clinic, it's an exciting time to be in the targeted radiopharmaceuticals space! The 2nd Annual Targeted Radiopharmaceuticals Summit US returns as the only industry-led meeting dedicated to accelerating TRP programs by discovering more-specific tumur-associated targets, increasing access and low-cost availability of radionuclides, and maximizing preclinical and clinical search of combination therapy with agents and treatment modalities. Join us as we unite 100+ key stakeholders across the space from large pharma, biotech, academia, physicians, nuclear physicists, cyclotron providers, manufacturers, linker developers, TRP-experienced CROs and many more, to bring the targeted radiotherapies to the forefront of cancer treatment. Take this unique opportunity to connect with all the key players in the targeted radiopharmaceuticals space as they learn the ins-and-outs of the progress, gain a deep and holistic insight of the current state-of-play in the US TRP landscape, and challenges the leading experts in the space are experiencing. URLs:Tickets: https://go.evvnt.com/1644812-2?pid=5569 Brochure: https://go.evvnt.com/1644812-3?pid=5569  Date and Time: On Tue, 25 Jul 2023 09:00 - Thu, 27 Jul 2023 16:30 Venue details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States Prices:Drug Developer Pricing - FULL PACKAGE: Conference + Workshop Day: USD 4297.00,Drug Developer Pricing - Conference Only: USD 2999.00,Academic Pricing - FULL PACKAGE: Conference + Workshop Day: USD 3697.00,Academic Pricing - Conference Only: USD 2599.00,Vendor Pricing - FULL PACKAGE: Conference + Workshop Day: USD 5297.00,Vendor Pricing - Conference Only: USD 3799.00 Speakers: Colin Hayward, Chief Medical Officer, Telix Pharmaceuticals, David Mankoff, Matthew J. Wilson Professor and Vice-Chair for Research, University of Pennsylvania, Erik Mittra, Director of Targeted Radionuclide Therapy, OHSU - Oregon Health and Science University, Ian Wilson, Chief Executive Officer, Imaginab, Jason Hurt, Chief Medical Officer, OranoMed, Julia Brosch-Lenz, Medical Physicist, Inserm Lille Neuroscience and Cognition research centre, Luke Nordquist, Chief Executive Officer, Urology Cancer Center and GU Research, Manuel Bardies, Research Director, Inserm, Marc Hedrick, Chief Executive Officer, Plus Therapeutics Inc, Melissa Moore, Vice President of Clinical Research, PLUS Therapeutics, Michael Shultz, Co-founder and Chief Scientific Officer, ViewPoint Therapeutics, Mike Sirosky, Product Manager, MIM Software, Mohit Rawat, President and Chief Business Officer, Fusion Pharmaceuticals, Munir Ghesani, Chief of Nuclear Medicine, Icahn School of Medicine at Mount Sinai, Neil Quigley, ITM Global Product Manager, ITM, Norman La France, Chief Medical Officer and Senior Vice President, PLUS Therapeutics, Paddy Gilligan, President, European Federation of Organisations for Medical Physics, Patrick Donahue, Chief Executive Officer, Iotron Medical Inc., Riccardo Canevari, Chief Executive Officer, Radiopharm Theranostics, Sandesh Seth, Chief Executive Officer, Actinium Pharmaceuticals, Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals, Sherly Mosessian, Chief Scientific Officer, SOFIE, Shiva Kazerounian, Director of Cancer Biology, Ratio Therapeutics, Sujiet Puthenveetil, Director, AstraZeneca, Susan Moran, Chief Medical Officer, RayzeBio